Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).

Pharmacol Res Perspect · 2021 · PMC8177063 · PMID 34087050

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

16 The IMPRESS trial showed a trend towards reduced mortality and heart failure morbidity in patients with reduced ejection fractions treated with omapatrilat ( N = 573). 16 However, comparison of omapatrilat to enalapril in the Phase 3 OVERTURE heart failure trial ( N = 2886) and in the OCTAVE hypertension trial ( N = 12,668) re

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.